The FDA NDA acceptance is a high-impact catalyst with a clear timeline; traders should monitor for potential approval ahead of the December 2026 PDUFA date. While the OSA trial missed its primary endpoint, the strong BP reduction supports continued development in hypertension. The improved cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
Mineralys Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighted by a significant reduction in net loss due to lower R&D spending following the completion of its pivotal lorundrostat trials. The company also announced FDA acceptance of its NDA for lorundrostat in hypertension, with a PDUFA date of December 22, 2026, marking a major regulatory milestone. Cash reserves increased to $656.6 million, sufficient to fund operations into 2028.
Key Financial Metrics
Key Facts
- FDA accepted NDA for lorundrostat with PDUFA target date of December 22, 2026
- Cash, cash equivalents, and investments totaled $656.6 million as of December 31, 2025, up from $198.2 million in 2024
- Net loss decreased to $154.7 million in 2025 from $177.8 million in 2024
- R&D expenses declined to $132.0 million in 2025 from $168.6 million in 2024 due to completion of pivotal trials
- G&A expenses increased to $38.6 million in 2025 from $23.8 million in 2024 due to headcount growth and professional fees
- Lorundrostat failed to meet primary endpoint in Explore-OSA Phase 2 trial for obstructive sleep apnea, but showed significant blood pressure reduction
Financial Impact
Reduced annual R&D spend by $36.6 million and improved cash position by $458.4 million year-over-year; net loss reduced by $23.1 million despite higher G&A
Risk Factors
- Lorundrostat may not gain FDA approval despite NDA acceptance
- Failure in the OSA indication limits expansion potential
- Increased G&A spending could pressure margins if revenue is delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255107 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 3 | $26.09 $28.20 | ▲ +8.09% | ▲ +9.83% | $23.56 (−9.70%) |
Jul 23, 2026 10w ago | Insider Cluster | $26.71 $25.65 | ▼ −3.97% | ▼ −7.59% | $23.56 (−11.79%) |
Jul 21, 2026 10w ago | Insider Cluster | $27.52 $26.61 | ▼ −3.31% | ▼ −5.87% | $23.56 (−14.39%) |
Jul 16, 2026 11w ago | Insider Cluster | $27.08 $26.09 | ▼ −3.66% | ▼ −7.27% | $23.56 (−13.00%) |
Jun 30, 2026 13w ago | 144 | $26.89 $26.35 | ▼ −2.01% | ▲ +0.18% | $23.56 (−12.38%) |
Jun 29, 2026 13w ago | 144 | $26.88 $26.71 | ▼ −0.63% | ▼ −0.35% | $23.56 (−12.35%) |
Jun 18, 2026 15w ago | Insider Cluster | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 17, 2026 15w ago | 144 | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.94 $28.96 | ▲ +20.97% | ▲ +19.08% | $23.56 (−1.59%) |
Jun 3, 2026 17w ago | 8-K | $25.06 $27.69 | ▲ +10.49% | ▲ +11.49% | $23.56 (−5.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access